What Are the Adverse Effects of CBD? A Scientific Overview - Mustaf Medical

Adverse Effects of CBD: What the Research Shows

Introduction

Maria works long hours at a tech startup and often wakes up feeling restless. After reading about cannabidiol (CBD) on a wellness blog, she bought a CBD gummies product for humans hoping to improve sleep and lower daily tension. While many users report mild benefits, the scientific community continues to investigate whether CBD can also produce unwanted effects, especially when taken regularly or in higher doses. This article explores the current evidence on adverse effects, how they arise, and what factors may influence individual risk. Understanding the research helps consumers make informed choices and discuss options with health professionals.

Background

Adverse effects refer to any undesirable physiological or psychological changes that occur after using a substance, even when the product is marketed as "natural." CBD is a phytocannabinoid extracted from the Cannabis sativa plant. Unlike Δ⁹‑tetrahydrocannabinol (THC), CBD does not produce intoxication, yet it interacts with the endocannabinoid system and several other receptors. Over the past decade, interest in CBD has surged, prompting a growing body of clinical and epidemiological studies. Most research focuses on therapeutic potentials such as anxiety reduction, seizure control, or pain relief, but safety data are equally important. Reports of side effects range from mild (dry mouth, drowsiness) to more serious concerns (liver enzyme elevations, drug interactions). The variability of findings reflects differences in formulation (oil, isolate, gummies), dosage, duration of use, and participant characteristics. Consequently, health agencies-including the World Health Organization and the U.S. Food and Drug Administration-advise caution and call for larger, well‑controlled trials to clarify the risk profile.

Science and Mechanism

When CBD is ingested, it undergoes first‑pass metabolism in the liver, where the enzyme cytochrome P450 (CYP3A4 and CYP2C19) converts it into multiple metabolites, the most prominent being 7‑hydroxy‑CBD. Bioavailability differs markedly by delivery method: oral gummies typically deliver 4‑6 % of the dose into systemic circulation, whereas sublingual oils may achieve 10‑20 % due to bypassing part of the gastrointestinal tract. After absorption, CBD binds weakly to CB1 and CB2 receptors yet modulates them indirectly, leading to downstream effects on neurotransmitter release, calcium signaling, and inflammatory pathways.

Strong evidence supports several mechanistic pathways for side effects:

  1. Enzyme inhibition – In vitro studies show CBD can inhibit CYP2C19 and CYP3A4, potentially raising plasma concentrations of co‑administered drugs such as anticoagulants, antiepileptics, and certain antidepressants. Clinical observations from a 2023 multicenter trial (GreenLeaf Labs) reported modest increases in serum levels of clobazam when participants used 600 mg/day of full‑spectrum CBD oil, prompting dosage adjustments.

  2. Receptor modulation – At higher concentrations, CBD may act as an agonist at serotonin 5‑HT₁A receptors, which can produce transient dizziness or increased sedation. A double‑blind crossover study in 2022 found that 25 % of participants experienced mild drowsiness after a single 30 mg dose of CBD isolate, resolving within two hours.

  3. Gastrointestinal impact – Oral CBD can irritate the intestinal lining, especially when formulated with high‑fat carriers. Participants in a 2024 observational cohort reported nausea and abdominal discomfort after ingesting more than 50 mg of CBD gummies per day for several weeks.

  4. adverse effects of cbd

    Hepatic effects – Animal models demonstrate dose‑dependent elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Human data are limited but suggest that chronic high‑dose use (≥ 1,000 mg/day) may increase liver enzymes in a subset of patients, particularly those with pre‑existing liver disease. The FDA‑approved drug Epidiolex (purified CBD) includes a label warning about potential hepatic injury, underscoring the relevance of dosage.

Emerging evidence points to variability based on genetics, age, and concurrent lifestyle factors. For example, polymorphisms in CYP2C19 can alter CBD metabolism, leading to higher systemic exposure and a greater chance of adverse reactions. Similarly, older adults often experience reduced hepatic clearance, increasing susceptibility to liver‑related effects. While most reported side effects are mild and reversible, the lack of long‑term safety data beyond six months warrants caution, especially for daily users of CBD gummies.

Comparative Context

Source / Form Absorption / Metabolic Impact Intake Ranges Studied Limitations Populations Studied
CBD gummies (sweetened) Low oral bioavailability; first‑pass hepatic metabolism 5 – 50 mg/day Variable carrier fat content Young adults, occasional users
Full‑spectrum CBD oil Moderate bioavailability; includes minor cannabinoids 25 – 600 mg/day Potential THC trace Epilepsy patients, chronic pain sufferers
CBD isolate (capsule) Higher purity, similar oral absorption to gummies 10 – 300 mg/day No entourage effect Healthy volunteers, clinical trials
Hemp seed (food) Minimal CBD content; primarily nutritional protein/fiber < 5 mg/day Inconsistent CBD concentration General population, dietary studies

Population Trade‑offs

  • Gummies are convenient for those preferring discreet dosing, yet the low bioavailability means higher grams of product may be needed to reach therapeutic levels, increasing exposure to excipients that can cause gastrointestinal upset.
  • Full‑spectrum oil offers the "entourage effect," potentially enhancing efficacy, but the presence of trace THC may be problematic for individuals undergoing drug testing or sensitive to psychoactive compounds.
  • Isolate capsules provide a clear dosage without additional cannabinoids, allowing precise titration, though they lack the synergistic benefits observed with full‑spectrum formulations.
  • Hemp seed contributes minimal CBD but supplies valuable nutrients; its adverse‑effect profile aligns more with typical food tolerability than with pharmacological agents.

Safety Considerations

The overall safety profile of CBD appears favorable at low to moderate doses, yet several groups should exercise heightened vigilance:

  • Pregnant or breastfeeding individuals – Animal studies suggest possible developmental toxicity at high exposure levels, and human data are insufficient. Health agencies generally advise against CBD use during pregnancy and lactation.
  • People with liver disease – Because CBD is metabolized hepatically, individuals with cirrhosis or hepatitis may experience amplified enzyme elevations. Monitoring liver function tests before and during use is recommended.
  • Patients on prescription medications – The enzyme‑inhibition potential of CBD raises the risk of pharmacokinetic interactions. Clinicians often recommend dose adjustments or alternative therapies when initiating CBD, particularly for antiepileptic drugs, warfarin, and certain antidepressants.
  • Elderly users – Age‑related declines in renal and hepatic clearance can prolong CBD's half‑life, possibly intensifying sedation, dizziness, or orthostatic hypotension. Starting with the lowest effective dose is advised.

Commonly reported side effects include dry mouth, reduced appetite, diarrhea, and mild fatigue. These events are typically transient and resolve upon dose reduction or discontinuation. Severe adverse reactions such as hepatic injury, significant hypotension, or allergic dermatitis are rare but have been documented in case reports. Because product quality varies widely across the market, contaminants (e.g., pesticides, heavy metals) may contribute to unexpected effects. Third‑party testing and sourcing from reputable manufacturers help mitigate this risk.

Frequently Asked Questions

Can CBD cause changes in liver enzymes?
Evidence from clinical trials of high‑dose CBD (≥ 1,000 mg/day) indicates modest increases in ALT and AST in some participants, particularly those with underlying liver conditions. Routine monitoring is advisable for anyone using CBD long‑term at elevated doses, but low‑dose gummy consumption (≤ 30 mg/day) has not consistently demonstrated hepatic toxicity in healthy adults.

Is drowsiness a common side effect?
Yes, mild sedation or daytime sleepiness is reported in up to 15 % of users, especially when CBD is taken in the evening or combined with other CNS depressants. The effect appears dose‑dependent; lower doses (5‑15 mg) usually produce minimal sedation, while doses above 50 mg may lead to noticeable drowsiness.

How does CBD interact with prescription medications?
CBD can inhibit CYP2C19 and CYP3A4 enzymes, potentially raising blood levels of drugs metabolized by these pathways (e.g., clobazam, certain antiretrovirals, and benzodiazepines). Interaction severity varies by individual metabolism and dosage, so consulting a healthcare professional before starting CBD-particularly for patients on multiple prescriptions-is essential.

Are pregnant or breastfeeding individuals advised to use CBD?
Current guidelines recommend avoiding CBD during pregnancy and lactation due to insufficient human safety data and animal studies suggesting possible developmental risks at high exposures. Health providers typically suggest alternative, well‑studied approaches for managing anxiety or sleep disturbances in these populations.

What is the risk of gastrointestinal upset with CBD gummies?
Oral CBD, especially when formulated with sugar alcohols or high‑fat carriers, can cause nausea, stomach cramps, or diarrhea in some individuals. Incidence rates range from 5‑10 % in clinical trial participants, often correlating with higher daily intakes (> 50 mg). Adjusting the dose or switching to a different delivery form (e.g., oil) usually alleviates these symptoms.

Disclaimer

This content is for informational purposes only. Always consult a healthcare professional before starting any supplement.